John A Hickman

List of Publications by Year
in descending order

65 papers	7,520 citations	87723 38 h-index	106150 65 g-index
67 all docs	67 docs citations	67 times ranked	11800 citing authors

#	Article	IF	Citations
1	The European Union and personalised cancer medicine. European Journal of Cancer, 2021, 150, 95-98.	1.3	5
2	S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget, 2018, 9, 20075-20088.	0.8	82
3	Limits to Precision Cancer Medicine. New England Journal of Medicine, 2017, 376, 95-97.	13.9	19
4	Limits to Personalized Cancer Medicine. New England Journal of Medicine, 2016, 375, 1289-1294.	13.9	329
5	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 2016, 538, 477-482.	13.7	830
6	Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices. Scientific Reports, 2015, 5, 17187.	1.6	98
7	Threeâ€dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo. Biotechnology Journal, 2014, 9, 1115-1128.	1.8	316
8	S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab. Molecular Cancer Therapeutics, 2013, 12, 1749-1762.	1.9	78
9	N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death. Nature Neuroscience, 2012, 15, 574-580.	7.1	70
10	An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells. Cancer Letters, 2010, 289, 178-187.	3.2	21
11	Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction. Science Signaling, 2009, 2, ra80.	1.6	84
12	Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. Journal of Cell Biology, 2009, 185, 279-290.	2.3	132
13	Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. Journal of Experimental Medicine, 2009, 206, i8-i8.	4.2	0
14	Bcl-x _L induces Drp1-dependent synapse formation in cultured hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2169-2174.	3.3	210
15	Bcl-xL Inhibitor ABT-737 Reveals a Dual Role for Bcl-xL in Synaptic Transmission. Journal of Neurophysiology, 2008, 99, 1515-1522.	0.9	49
16	BH3-Only Proteins and BH3 Mimetics Induce Autophagy by Competitively Disrupting the Interaction between Beclin 1 and Bcl-2/Bcl-X_L. Autophagy, 2007, 3, 374-376.	4.3	411
17	Cell Cycle-Dependent Induction of Autophagy, Mitophagy and Reticulophagy. Cell Cycle, 2007, 6, 2263-2267.	1.3	117
18	Novel Stable Camptothecin Derivatives Replacing the E-Ring Lactone by a Ketone Function Are Potent Inhibitors of Topoisomerase I and Promising Antitumor Drugs. Molecular Pharmacology, 2007, 72, 311-319.	1.0	28

#	Article	IF	Citations
19	Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1. EMBO Journal, 2007, 26, 2527-2539.	3.5	1,003
20	Exposure to Hypoxia Rapidly Induces Mitochondrial Channel Activity within a Living Synapse. Journal of Biological Chemistry, 2005, 280, 4491-4497.	1.6	45
21	Covalent binding of antitumor benzoacronycines to double-stranded DNA induces helix opening and the formation of single-stranded DNA: unique consequences of a novel DNA-bonding mechanism. Molecular Cancer Therapeutics, 2005, 4, 71-80.	1.9	34
22	Proapoptotic N-truncated BCL-xL protein activates endogenous mitochondrial channels in living synaptic terminals. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13590-13595.	3.3	95
23	Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1644, 251-260.	1.9	54
24	Structureâ^'Activity Relationships and Mechanism of Action of Antitumor Benzo[b]pyrano[3,2-h]acridin-7-one Acronycine Analogues. Journal of Medicinal Chemistry, 2003, 46, 3072-3082.	2.9	52
25	Decrease in Survival Threshold of Quiescent Colon Carcinoma Cells in the Presence of a Small Molecule Integrin Antagonist. Molecular Pharmacology, 2003, 63, 1281-1288.	1.0	13
26	Post-translational Modification of Bid Has Differential Effects on Its Susceptibility to Cleavage by Caspase 8 or Caspase 3. Journal of Biological Chemistry, 2003, 278, 15749-15757.	1.6	67
27	Modulation of Synaptic Transmission by the BCL-2 Family Protein BCL-xL. Journal of Neuroscience, 2003, 23, 8423-8431.	1.7	95
28	Acronycine derivatives as promising antitumor agents. Anti-Cancer Drugs, 2002, 13, 445-449.	0.7	38
29	Alkylation of Guanine in DNA by S23906-1, a Novel Potent Antitumor Compound Derived from the Plant Alkaloid Acronycineâ€. Biochemistry, 2002, 41, 9911-9920.	1.2	64
30	Apoptosis and tumourigenesis. Current Opinion in Genetics and Development, 2002, 12, 67-72.	1.5	96
31	Induction of apoptosis in HL-60 leukemia and B16 melanoma cells by the acronycine derivative S23906-1. Biochemical Pharmacology, 2002, 63, 1443-1452.	2.0	39
32	Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak. Oncogene, 2001, 20, 7668-7676.	2.6	84
33	Induction of Cyclin E and Inhibition of DNA Synthesis by the Novel Acronycine Derivative S23906-1 Precede the Irreversible Arrest of Tumor Cells in S Phase Leading to Apoptosis. Molecular Pharmacology, 2001, 60, 1383-1391.	1.0	73
34	Bid, a Widely Expressed Proapoptotic Protein of the Bcl-2 Family, Displays Lipid Transfer Activity. Molecular and Cellular Biology, 2001, 21, 7268-7276.	1.1	124
35	Apoptosis and cancer chemotherapy. Cell and Tissue Research, 2000, 301, 143-152.	1.5	188
36	Epigenetic Determinants of Resistance to Etoposide Regulation of Bcl-xL and Bax by Tumor Microenvironmental Factors. Journal of the National Cancer Institute, 2000, 92, 18-23.	3.0	119

#	Article	IF	Citations
37	Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis. Journal of Cell Biology, 1999, 144, 903-914.	2.3	413
38	Nucleolar segregation during apoptosis of haemopoietic stem cell line FDCP-Mix1. Cell Death and Differentiation, 1999, 6, 334-341.	5.0	19
39	Bcl-2 overexpression results in reciprocal downregulation of Bcl-XL and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene, 1999, 18, 1457-1464.	2.6	74
40	Damage-induced apoptosis in intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo. Oncogene, 1999, 18, 7287-7293.	2.6	98
41	Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers. Cell Death and Differentiation, 1998, 5, 107-115.	5.0	110
42	Different cell thresholds for commitment to death: a link between carcinogenesis and drug resistance. Drug Resistance Updates, 1998, 1, 84-85.	6.5	4
43	Radiation-Induced p53 and p21WAFâ€“1/CIP1 Expression in the Murine Intestinal Epithelium. American Journal of Pathology, 1998, 153, 899-909.	1.9	101
44	Chemically-induced apoptosis: p21 and p53 as determinants of enterotoxin activity. Toxicology Letters, 1998, 102-103, 19-27.	0.4	18
45	Cell cycle specific induction of HL-60 cell differentiation and apoptosis by mycophenolic acid. Cell Death and Differentiation, 1997, 4, 787-795.	5.0	11
46	Apoptosis in small intestinal epithelia from p53-null mice: evidence for a delayed, p53-indepdendent G2/M-associated cell death after Î³-irradiation. Oncogene, 1997, 14, 2759-2766.	2.6	213
47	MCF-7 human mammary adenocarcinoma cell deathin vitro in response to hormone-withdrawal and dna damage. International Journal of Cancer, 1995, 61, 502-508.	2.3	51
48	Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells. Cytometry, 1995, 20, 245-256.	1.8	61
49	Mechanisms of cytotoxicity caused by antitumour drugs. Toxicology Letters, 1992, 64-65, 553-561.	0.4	20
50	Apoptosis induced by anticancer drugs. Cancer and Metastasis Reviews, 1992, 11, 121-139.	2.7	820
51	Selective inhibition by bis(2-chloroethyl)methylamine (nitrogen mustard) of the Na+/K+/Clâ^' cotransporter of murine L1210 leukemia cells. Biochimica Et Biophysica Acta - Biomembranes, 1988, 946, 368-378.	1.4	12
52	Alkylformamides as inducers of tumour cell differentiation â€" a mini-review. Toxicology, 1987, 43, 239-249.	2.0	12
53	The formation and metabolism of N-hydroxymethyl compoundsâ€"IX. Biochemical Pharmacology, 1986, 35, 4161-4165.	2.0	1
54	Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogs of N-methylformamide. Journal of Medicinal Chemistry, 1986, 29, 1046-1052.	2.9	39

#	Article	IF	Citations
55	The generation of potentially toxic, reactive iminium ions from the oxidative metabolism of xenobiotic N-alkyl compounds. Biochemical Pharmacology, 1985, 34, 2055-2061.	2.0	34
56	Cell Surface Membranes as a Chemotherapeutic Target. Cancer Treatment and Research, 1985, , 81-131.	0.2	20
57	Membrane targets in cancer chemotherapy. Trends in Pharmacological Sciences, 1984, 5, 15-17.	4.0	25
58	The formation and metabolism of N-hydroxymethyl compoundsâ€"III. Biochemical Pharmacology, 1983, 32, 1773-1781.	2.0	25
59	The role of isocyanates in the toxicity of antitumour haloalkylnitrosoureas. Biochemical Pharmacology, 1982, 31, 2795-2800.	2.0	28
60	Studies of the mode of action of antitumour triazenes and triazinesâ€"IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethyltriazene. Biochemical Pharmacology, 1982, 31, 1887-1892.	2.0	14
61	The formation and metabolism of N-hydroxymethyl compoundsâ€"I. Biochemical Pharmacology, 1982, 31, 3621-3627.	2.0	15
62	The effects of nitrogen mustard (HN2) on activities of the plasma membrane of PC6A mouse plasmacytoma cells. Biochemical Pharmacology, 1982, 31, 1773-1778.	2.0	31
63	Studies of the mode of action of antitumour triazenes and triazinesâ€"II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenes. Biochemical Pharmacology, 1981, 30, 89-93.	2.0	30
64	Oxidative metabolism of some N-methyl containing xenobiotics can lead to stable progenitors of formaldehyde. Biochemical Pharmacology, 1979, 28, 3235-3238.	2.0	24
65	Î±-hydroxylated derivatives of antitumour dimethyltriazenes. Tetrahedron Letters, 1978, 19, 5041-5044.	0.7	33